首页 | 本学科首页   官方微博 | 高级检索  
检索        

迈之灵治疗中心性浆液性脉络膜视网膜病变
引用本文:王卫峻,宫媛媛,王泓,吴颖,吴星伟,许迅.迈之灵治疗中心性浆液性脉络膜视网膜病变[J].中国新药与临床杂志,2005,24(12):961-964.
作者姓名:王卫峻  宫媛媛  王泓  吴颖  吴星伟  许迅
作者单位:上海交通大学附属上海市第一人民医院,眼科,上海,200080
摘    要:目的:探讨迈之灵治疗中心性浆液性脉络膜视网膜病变(CSC)的临床效果及光学相干断层成像(OCT)的运用价值。方法:33例(36眼)临床诊断为CSC的病人随机分为2组,芦丁组15例(15眼),迈之灵组18例(21眼),分别给予迈之灵和复方芦丁片口服,2片,每日3次,均4wk为一个疗程,随访12wk。比较2组在治疗前后logMAR对数视力变化,并通过OCT检查,比较治疗前后视网膜神经上皮和(或)色素上皮脱离程度的变化。结果:治疗wk2,迈之灵组视力改善优于芦丁组,差异有显著意义(P<0.05);治疗wk4和wk12,2组无显著差异(P>0.05)。治疗wk2和wk4,迈之灵组视网膜脱离面积减小(116347±s88445)和(171104±120636)μm2,减小幅度大于芦丁组(53858±46561)和(85486±114607)μm2,差异有显著意义(P<0.05),治疗wk12时2组间无显著差异(P>0.05)。2组均无不良反应。结论:迈之灵治疗CSC,可缩短病人主观视力改善及黄斑部水肿消退的时间。OCT能客观、定量地进行黄斑部微结构的测量和分析,对CSC治疗效果的评价有一定价值。

关 键 词:视网膜疾病  脉络膜疾病  七叶素  中心性浆液性脉络膜视网膜病变  光学相干断层成像  迈之灵
文章编号:1007-7669(2005)12-0961-04
收稿时间:2005-07-04
修稿时间:2005-07-042005-10-18

Aescuven forte in treating central serous chorioretinopathy
WANG Wei-jun,GONG Yuan-yuan,WANG Hong,WU Ying,WU Xing-wei,XU Xun.Aescuven forte in treating central serous chorioretinopathy[J].Chinese Journal of New Drugs and Clinical Remedies,2005,24(12):961-964.
Authors:WANG Wei-jun  GONG Yuan-yuan  WANG Hong  WU Ying  WU Xing-wei  XU Xun
Abstract:AIM:To investigate the therapeutic effect of aescuven forte in treating central serous chorioretinopathy (CSC) and application value of optical coherence tomography (OCT). METHODS: Thirty-three patients (36 eyes) with CSC were randomly divided into two groups. Fifteen patients (15 eyes) were enrolled in rutoside group and 18 patients (21 eyes) in aescuven forte group, receiving compound rutoside and aescuven forte, 2 tablets, po, tid, respectively for 12 wk. The visual acuities and the results of OCT in both groups for detecting the retinal neuroepithelia or pigmented epithelial detachment were observed before and after the treatment. RESULTS: The improvement of visual acuity in aescuven forte group was significantly better than that in rutoside group 2 wk after the treatment(P<0.05). There was no significant difference in visual acuity between two groups at 4, 12 wk after the treatment (P>0.05). At 2 and 4 wk after therapy, the area of retina detactment in aescuven forte group decreased significantly(116 347±s 88 445)and(171 104±120 636) μm2, more than those in rutoside group ((53 858±46 561),(85 486± 114 607) μm2,P<0.05). There was no difference between two groups 12 wk after the therapy (P> 0.05). No obvious adverse reactions occurred in both groups. CONCLUSION: Aescuven forte in treating CSC can improve visual acuity and erase the macular edema much sooner. As a non-contact and non-invasive diagnosis technique, OCT provides objective documentation of foveal structural changes in eyes with CSC, and is helpful to assessment the therapeutic effect of CSC.
Keywords:retinal disease  chorioid disease  escin  central serous chorioretinopathy  optical coherence tomography  aescuven forte
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号